Responses
Regular and Young Investigator Award Abstracts
Immune-Stimulants and Immune Modulators
702 TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumor-dependent immune response without dose-limiting toxicity in preclinical studies
Compose a Response to This Article
Other responses
No responses have been published for this article.